MOCS1
Molybdenum cofactor biosynthesis protein 1
As of the edition of 20 October 2026, MOCS1 (molybdenum cofactor biosynthesis protein 1, UniProt Q9NZB8) has 1 drug tested at it and 4 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NZB8
- How well studied
- Drug target: an approved drug acts on it
- Registered trials of its drugs
- 2
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Fosdenopterin | Marketed | Phase 2 | Ends 2028 |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Undetermined | 2 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Sentynl Therapeutics | Route B |
| TMC Pharma | Route B |
The other 2 companies at MOCS1
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at MOCS1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.